The most frequent cause of treatment failure after allogeneic stem cell transplantation (SCT) for leukemia is relapse of the underlying host leukemia. However, rare cases have been reported in which cytogenetic analysis, alone or in combination with molecular analysis, has indicated that the new leukemia originated in the donor cells. 1 Donor cell leukemia (DCL) is a rare event of unknown incidence after allogeneic SCT.
We report a patient with acute myeloid leukemia (AML) (FAB M0) who developed an AML (FAB M2) in the donor cells 11 months after unrelated cord blood transplantation (CBT). A 32-year-old woman complained of fever having an unknown origin, and she had a diagnosis of AML (FAB M0) (peroxidase staining negative, CD13 þ , CD33 þ , CD34 þ ). Cytogenetic studies showed a chromosomal abnormality with 47, XX, add (10)(p11), À11,?13p, þ mar1 Â 2 (20/20). She achieved complete remission with two courses of remission induction therapies. Three courses of consolidation and three courses of intensification therapies were then given sequentially. Her conditioning regimen consisted of 8 g/m 2 of cytosine arabinoside, 120 mg/kg of cyclophosphamide and 12 Gy of total body irradiation (TBI) divided into six fractions over 3 days, and she received CBT from a two HLA loci-mismatched unrelated female donor. The total number of infused nucleated cells was 2.90 Â 10 7 /kg, CD34 þ cells were 1.74 Â 10 5 /kg, and CFU-GM were 2.56 Â 10 4 /kg. GVHD prophylaxis was 3 mg/kg of cyclosporine A (CsA) and short-term methotrexate. Her peripheral blood leukocyte count reached more than 1.0 Â 10 9 /l on day þ 20 post-CBT. Engraftment of donor cells was confirmed by short tandem repeat (STR) analysis on day þ 26 (data not shown). She had acute GVHD (skin stage 3, Grade II) and bronchiolites obliterans organizing pneumonia. We stopped her regimen to administer steroid and CsA for treatment of GVHD and BOOP on day þ 135 and day þ 191, respectively. Examination of her bone marrow on day þ 241 revealed the presence of 7% atypical early cells. However, STR analysis on day þ 253 showed that these cells were completely of the donor type (Figure 1) . Therefore, we carried out FACS analysis of her bone marrow cells, and this revealed that the atypical early cells expressed CD10, CD19 and CD20. In addition, STR analysis of the bone marrow cells on day þ 301 also showed that the atypical cells were completely of the donor type (Figure 1 ). At this point in time, we diagnosed hematogone. 2 However, her peripheral blood contained 9% blast cells, and her bone marrow also contained 20% blast cells on day þ 335. As for the character of the blast cells, peroxidase staining was positive and CD13 and CD33 were positive. On the other hand, CD34 was negative. The phenotype of the blast cells differed from M0. Her leukemic cells had only a normal karyotype (46 XX 20/20), and STR analysis of her peripheral blood, which included 13% blast cells, revealed that the atypical cells were completely of the donor type (Figure 1 ). Her leukemic cells increased to 44% in the bone marrow on day þ 338; therefore, we began reinduction therapy starting on day þ 343. Examination of her bone marrow 4 weeks after the start of her re-induction therapy showed that the hypoplastic marrow still contained 26.2% blast cells. At this point, she received a reduced-intensity conditioning SCT from her younger brother, with two HLA loci mismatched, at another hospital. Engraftment was prompt and she achieved complete remission. However, she developed a thrombotic microangiopathy, and she passed away owing to this complication.
The development of DCL after allogeneic SCT is a very rare event. Witherspoon et al. 3 reported six cases of secondary leukemia among 2246 bone marrow transplantations. Four of these were DCL in which the secondary leukemia from the host cells differed from the primary disease morphologically. DCL arising after SCT might be underestimated, as chimerism analysis is often difficult and cytogenetic studies alone are sometimes misleading. 4 In our case, cytogenetic study at relapse after CBT indicated a normal karyotype, despite the fact that chromosomal abnormalities were noted at the initial diagnosis. Furthermore, molecular analysis using STR proved the de novo leukemia to be of donor origin. In bone marrow transplantation, the average onset time for DCL is 30 months (from 2 months to 11 years) from transplantation to relapse, 1 which is longer than the average relapse with a host cell origin. Our case occurred 11 months following transplantation, and thus belongs to an early onset class of donor cell-origin leukemia. The analysis of DCL has provided a few insights into leukemogenesis. Postulated mechanisms for development of DCL include (1) occult leukemia in the donor, (2) transfer of oncogenic material from host to donor cells, (3) impaired immune surveillance, (4) drug therapy (delayed effects of various pre-transplant conditioning regimens may last long enough to affect the newly arriving donor cells) and so on. Nevertheless, it has never been possible to prove the exact mechanism responsible for DCL development on an individual basis.
In recent years, cord blood (CB) has emerged as a feasible alternative source of hematopoietic progenitors for allogeneic SCT, and this is most applicable to patients who lack an HLAmatched marrow donor. The naive nature of CB lymphocytes permits the use of HLA-mismatched grafts at 1-2 loci, and there is not a higher risk for severe GVHD relative to the risk associated with bone marrow transplantation from a fully matched unrelated donor. As a result, CBT has recently been explored for an increasing number of adult patients. Hematopoietic stem cells (HSC) derived from CB differ from those in the bone marrow or PBSC in several ways. The most notable difference is that the total cell number in CBT is significantly less than the HSC that can be obtained from adult sources, such as PBSC or marrow. There are also qualitative differences between CB and other HSC. For example, the proliferative capacity of progenitor cells in laboratory assays and of CB stem cells transplanted into immunodeficient mice was measurably higher than that of progenitors and stem cells from bone marrow. 5 Thus, the HSC in CB may be both primitive and more capable of regenerating hematopoiesis in the recipients. Furthermore, one of the notable differences between the T lymphocytes in CB and those derived from adult marrow or mobilized PBSC is their maturational status. As the fetus is exposed to few foreign antigens, the T lymphocytes in CB are almost exclusively naive. The predominant naive phenotype of T lymphocytes in CB may contribute to the reduced immune tumor surveillance. Two case reports of DCL after CBT have been published since the initial submission of this manuscript. 6, 7 Interestingly, all of three cases of DCL after CBT were AML, although there is a higher reported incidence of acute lymphoblastic leukemia in childhood. The full delineation of the underlying disease processes requires further extensive research. Finally, the development of DCL after CBT brings up a new type of ethical issue involving SCT. 7 In this case, the donor was healthy at medical checkup 1 year after birth. The possibility of an occult leukemia in the donor raises serious questions whether the cord blood bank should inform the risk to the donor. At present, there are not enough reported cases to accurately estimate the risk of developing donorderived leukemia after CBT.
